<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36680115</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Drug Repositioning for Hand, Foot, and Mouth Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">75</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15010075</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) is a highly contagious disease in children caused by a group of enteroviruses. HFMD currently presents a major threat to infants and young children because of a lack of antiviral drugs in clinical practice. Drug repositioning is an attractive drug discovery strategy aimed at identifying and developing new drugs for diseases. Notably, repositioning of well-characterized therapeutics, including either approved or investigational drugs, is becoming a potential strategy to identify new treatments for virus infections. Various types of drugs, including antibacterial, cardiovascular, and anticancer agents, have been studied in relation to their therapeutic potential to treat HFMD. In this review, we summarize the major outbreaks of HFMD and the progress in drug repositioning to treat this disease. We also discuss the structural features and mode of action of these repositioned drugs and highlight the opportunities and challenges of drug repositioning for HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Shenzhen University, Shenzhen 518060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jiahao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Shenzhen University, Shenzhen 518060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Shenzhen University, Shenzhen 518060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiapeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9275-1239</Identifier><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Shenzhen University, Shenzhen 518060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-7573-5288</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhendan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Shenzhen University, Shenzhen 518060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qinchang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">drug repositioning</Keyword><Keyword MajorTopicYN="N">drug repurposing</Keyword><Keyword MajorTopicYN="N">enteroviruses</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36680115</ArticleId><ArticleId IdType="pmc">PMC9861398</ArticleId><ArticleId IdType="doi">10.3390/v15010075</ArticleId><ArticleId IdType="pii">v15010075</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esposito S., Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:391–398. doi: 10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A., Bhatnagar J., Zaki S.R. Tissue tropism, pathology and pathogenesis of enterovirus infection. J. Pathol. 2015;235:217–228. doi: 10.1002/path.4438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4438</ArticleId><ArticleId IdType="pubmed">25211036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmis B.D., Downing C., Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018;102:353–356.</Citation><ArticleIdList><ArticleId IdType="pubmed">30566537</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.W., Ni X., Qian S.Y., Wang Q., Jiang R.M., Xu W.B., Zhang Y.C., Yu G.J., Chen Q., Shang Y.X., et al. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition) World J. Pediatr. 2018;14:437–447. doi: 10.1007/s12519-018-0189-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-018-0189-8</ArticleId><ArticleId IdType="pubmed">30280313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebnasagh A., Avan R., Saghafi F., Mojtahedzadeh M., Sadremomtaz A., Arasteh O., Tanzifi A., Faramarzi F., Negarandeh R., Safdari M., et al. Pharmacological treatments of COVID-19. Pharmacol. Rep. 2020;72:1446–1478. doi: 10.1007/s43440-020-00152-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-020-00152-9</ArticleId><ArticleId IdType="pmc">PMC7439639</ArticleId><ArticleId IdType="pubmed">32816200</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Peng T. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Front. Pharmacol. 2021;12:660710. doi: 10.3389/fphar.2021.660710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.660710</ArticleId><ArticleId IdType="pmc">PMC8129523</ArticleId><ArticleId IdType="pubmed">34017257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdan J.-P., Bureau R., Rochais C., Dallemagne P. Drug repositioning: A brief overview. J. Pharm. Pharmacol. 2020;72:1145–1151. doi: 10.1111/jphp.13273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.13273</ArticleId><ArticleId IdType="pmc">PMC7262062</ArticleId><ArticleId IdType="pubmed">32301512</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.L., Pan H., Liu P., Amer S., Chan T.C., Zhan J., Huo X., Liu Y., Teng Z., Wang L., et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev. Med. Virol. 2015;25:115–128. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y.F., Wee K.L., Chiam C.W., Khor C.S., Chan S.Y., Amalina W.M.Z., Sam I.C. Comparative genetic analysis of VP4, VP1 and 3D gene regions of enterovirus 71 and coxsackievirus A16 circulating in Malaysia between 1997–2008. Trop. Biomed. 2012;29:451–466.</Citation><ArticleIdList><ArticleId IdType="pubmed">23018509</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick J.L., Tagaya I., von Magnus H. Enteroviruses 69, 70, and 71. Intervirology. 1974;4:369–370. doi: 10.1159/000149872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000149872</ArticleId><ArticleId IdType="pubmed">4377266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K., Wang Y., Guo Z., Yu H., Li H., Zhang L., Xu S., Zhang Q. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China. BMC Infect. Dis. 2019;19:285. doi: 10.1186/s12879-019-3878-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3878-6</ArticleId><ArticleId IdType="pmc">PMC6438032</ArticleId><ArticleId IdType="pubmed">30917800</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick J.L., Schmidt N.J., Mirkovic R.R., Chumakov M.P., Lavrova I.K., Voroshilova M.K. Identification of Bulgarian strain 258 of enterovirus 71. Intervirology. 1980;12:297–302. doi: 10.1159/000149088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000149088</ArticleId><ArticleId IdType="pubmed">6244233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T.K. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 2010;14:e1076–e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusinszky B., Szomor K.N., Farkas A., Takács M., Berencsi G. Detection of non-polio enteroviruses in Hungary 2000–2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30. Virus Genes. 2010;40:163–173. doi: 10.1007/s11262-009-0440-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-009-0440-4</ArticleId><ArticleId IdType="pubmed">20044791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.-H., Huang L.M., Wong W.-W., Wu T.-Z., Chiu T.-F., Chang L.-Y. Molecular diagnosis and clinical presentations of enteroviral infections in Taipei during the 2008 epidemic. J. Microbiol. Immunol. Infect. 2011;44:178–183. doi: 10.1016/j.jmii.2011.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2011.01.018</ArticleId><ArticleId IdType="pubmed">21524611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortner B., Huang C.-W., Schmid D., Mutz I., Wewalka G., Allerberger F., Yang J.-Y., Huemer H.P. Epidemiology of enterovirus types causing neurological disease in Austria 1999–2007: Detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J. Med. Virol. 2009;81:317–324. doi: 10.1002/jmv.21374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21374</ArticleId><ArticleId IdType="pubmed">19107980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K., Aoki Y., Matoba Y., Yahagi K., Itagaki T., Katsushima F., Katsushima Y., Ito S., Hongo S., Matsuzaki Y. Molecular epidemiology of enterovirus 71 strains isolated from children in Yamagata, Japan, between 1990 and 2013. Pt 10J. Med. Microbiol. 2014;63:1356–1362. doi: 10.1099/jmm.0.079699-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.079699-0</ArticleId><ArticleId IdType="pubmed">25053796</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden S., Koopmans M., Uslu G., van der Avoort H. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J. Clin. Microbiol. 2009;47:2826–2833. doi: 10.1128/JCM.00507-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00507-09</ArticleId><ArticleId IdType="pmc">PMC2738086</ArticleId><ArticleId IdType="pubmed">19625480</ArticleId></ArticleIdList></Reference><Reference><Citation>Le T.V., Nguyen V.T.T., Nguyen Q.H., Pham D.T. Molecular epidemiology analysis of enterovirus 71 strains isolated in Dak Lak, Vietnam, 2011–2016. J. Med. Virol. 2019;91:56–64. doi: 10.1002/jmv.25286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25286</ArticleId><ArticleId IdType="pubmed">30132913</ArticleId></ArticleIdList></Reference><Reference><Citation>Badran S.A., Midgley S., Andersen P., Böttiger B. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand. J. Infect. Dis. 2011;43:642–648. doi: 10.3109/00365548.2011.577094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365548.2011.577094</ArticleId><ArticleId IdType="pubmed">21526904</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhmadishina L.V., Eremeeva T.P., Trotsenko O.E., Ivanova O.E., Mikhailov M.I., Lukashev A.N. Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia. PLoS ONE. 2014;9:e97404. doi: 10.1371/journal.pone.0097404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097404</ArticleId><ArticleId IdType="pmc">PMC4018281</ArticleId><ArticleId IdType="pubmed">24819617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.Y.Q., Gonfrier G., Ninove L., Zandotti C., Dubot-Pérès A., de Lamballerie X., Charrel R.N. Screening and detection of human enterovirus 71 infection by a real-time RT-PCR assay in Marseille, France, 2009–2011. Clin. Microbiol. Infect. 2012;18:E77–E80. doi: 10.1111/j.1469-0691.2012.03769.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03769.x</ArticleId><ArticleId IdType="pubmed">22332991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.H., Lau C.S., Cheng P.K.C., Ng A.Y.Y., Lim W.W.L. Coxsackievirus B3-associated aseptic meningitis: An emerging infection in Hong Kong. J. Med. Virol. 2011;83:483–489. doi: 10.1002/jmv.21998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21998</ArticleId><ArticleId IdType="pubmed">21264869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek M., Krzysztoszek A. Molecular Characterization of Enteroviruses Isolated from Acute Flaccid Paralysis Cases in Poland, 1999–2014. Pol. J. Microbiol. 2017;65:443–450. doi: 10.5604/17331331.1227670.</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/17331331.1227670</ArticleId><ArticleId IdType="pubmed">28735328</ArticleId></ArticleIdList></Reference><Reference><Citation>Laxmivandana R., Cherian S.S., Yergolkar P., Chitambar S.D. Genomic characterization of coxsackievirus type B3 strains associated with acute flaccid paralysis in south-western India. J. Gen. Virol. 2016;97:694–705. doi: 10.1099/jgv.0.000391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000391</ArticleId><ArticleId IdType="pubmed">26743460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H., Zhang Y., Sun Q., Zhu S., Li X., Pan Z., Xu W., Xu B. Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China: Outbreaks of coxsackieviruses a10 and b3. PLoS ONE. 2014;9:e84233. doi: 10.1371/journal.pone.0084233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084233</ArticleId><ArticleId IdType="pmc">PMC3879295</ArticleId><ArticleId IdType="pubmed">24392117</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z., Zhang Y., Huang K., Wang J., Tian H., Song Y., Yang Q., Yan D., Zhu S., Yao M., et al. Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect. Dis. 2019;19:466. doi: 10.1186/s12879-019-4107-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4107-z</ArticleId><ArticleId IdType="pmc">PMC6534883</ArticleId><ArticleId IdType="pubmed">31126252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., Liang Z. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum. Vaccin Immunother. 2014;10:360–367. doi: 10.4161/hv.27087.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson C.R., Doane F.W., Rhodes A.J. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can. Med. Assoc. J. 1958;79:615–621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1830188</ArticleId><ArticleId IdType="pubmed">13585281</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsop J., Flewett T.H., Foster J.R. “Hand-foot-and-mouth disease” in Birmingham in 1959. Br. Med. J. 1960;2:1708–1711. doi: 10.1136/bmj.2.5214.1708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.5214.1708</ArticleId><ArticleId IdType="pmc">PMC2098292</ArticleId><ArticleId IdType="pubmed">13682692</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson H.B., Leibovitz A. “Hand, Foot, and Mouth Disease” in Children.; an Epidemic Associated with Coxsakie Virus a-16. J. Pediatr. 1965;67:6–12. doi: 10.1016/S0022-3476(65)80297-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(65)80297-9</ArticleId><ArticleId IdType="pubmed">14301560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau H.F., Richter M., Doerr H.W. Hand, foot and mouth disease: Seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med. Microbiol. Immunol. 2010;199:45–51. doi: 10.1007/s00430-009-0133-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-009-0133-6</ArticleId><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalkrishna V., Patil P.R., Patil G.P., Chitambar S.D. Circulation of multiple enterovirus serotypes causing hand, foot and mouth disease in India. Pt 3J. Med. Microbiol. 2012;61:420–425. doi: 10.1099/jmm.0.036400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.036400-0</ArticleId><ArticleId IdType="pubmed">22052995</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S., Arunkumar G., Alidjinou E.K., Hober D. Hand, foot and mouth disease (HFMD): Emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 2016;205:397–407. doi: 10.1007/s00430-016-0465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Di B., Zhang Y., Xie H., Li X., Chen C., Ding P., He P., Wang D., Geng J., Luo L., et al. Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guangzhou, 2010–2012. Virol. J. 2014;11:157. doi: 10.1186/1743-422X-11-157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-157</ArticleId><ArticleId IdType="pmc">PMC4169826</ArticleId><ArticleId IdType="pubmed">25178398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A., Henquell C., Archimbaud C., Ughetto S., Antona D., Bailly J.L., Peigue-Lafeuille H. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: A large citywide, prospective observational study. Clin. Microbiol. Infect. 2012;18:E110–E118. doi: 10.1111/j.1469-0691.2012.03789.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zhu R., Huo D., Du Y., Yan Y., Liang Z., Luo Y., Yang Y., Jia L., Chen L., et al. An outbreak of Coxsackievirus A6-associated hand, foot, and mouth disease in a kindergarten in Beijing in 2015. BMC Pediatr. 2018;18:277. doi: 10.1186/s12887-018-1253-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-018-1253-1</ArticleId><ArticleId IdType="pmc">PMC6103857</ArticleId><ArticleId IdType="pubmed">30131060</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes M., Artieda J., Piñeiro L.D., Gastesi M., Diez-Nieves I., Cilla G. Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011. Emerg. Infect. Dis. 2013;19:676–678. doi: 10.3201/eid1904.121589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121589</ArticleId><ArticleId IdType="pmc">PMC3647425</ArticleId><ArticleId IdType="pubmed">23751014</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Chieochansin T., Linsuwanon P., Korkong S., Thongkomplew S., Vichaiwattana P., Theamboonlers A., Poovorawan Y. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg. Infect. Dis. 2013;19:641–643. doi: 10.3201/eid1904.121666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Mao Q., Sun S., Wu X., Liu S., Yang X., Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: More serious than it seems. Expert. Rev. Anti Infect. Ther. 2019;17:233–242. doi: 10.1080/14787210.2019.1585242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2019.1585242</ArticleId><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu P.-Y., Tyan Y.-C., Chen Y.-S., Chen H.-L., Lu P.-L., Chen Y.-H., Chen B.-C., Huang T.-S., Wang C.-F., Su H.-J., et al. Transmission and Demographic Dynamics of Coxsackievirus B1. PLoS ONE. 2015;10:e0129272. doi: 10.1371/journal.pone.0129272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129272</ArticleId><ArticleId IdType="pmc">PMC4460132</ArticleId><ArticleId IdType="pubmed">26053872</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Nonpolio enterovirus and human parechovirus surveillance—United States, 2006–2008. MMWR Morb. Mortal. Wkly. Rep. 2010;59:1577–1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">21150865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Kang B., Hwang S., Hong J., Chung J., Kim S., Jeong Y.-S., Kim K., Cheon D.-S. Molecular characteristics of human coxsackievirus B1 infection in Korea, 2008–2009. J. Med. Virol. 2013;85:110–115. doi: 10.1002/jmv.23359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23359</ArticleId><ArticleId IdType="pubmed">23073968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracho M.A., González-Candelas F., Valero A., Córdoba J., Salazar A. Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. Emerg. Infect. Dis. 2011;17:2223–2231. doi: 10.3201/eid1712.110395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1712.110395</ArticleId><ArticleId IdType="pmc">PMC3311182</ArticleId><ArticleId IdType="pubmed">22172227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Fan H., Lu P.-X., Zhang X.-F., Ai J., Shi C., Huo X., Bao C.-J., Shan J., Jin Y. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: Epidemiology, etiology, and disease burden. BMC Infect. Dis. 2019;19:79. doi: 10.1186/s12879-018-3659-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3659-7</ArticleId><ArticleId IdType="pmc">PMC6341624</ArticleId><ArticleId IdType="pubmed">30669973</ArticleId></ArticleIdList></Reference><Reference><Citation>de Cássia Compagnoli Carmona R., Machado B.C., de Sousa C.A., Vieira H.R., Alves M.R.M., de Souza K.A.F., de Souza Gregório D., Vilanova B.C., Timenetsky M.d.C.S.T. Distribution of species Enterovirus B in patients with central nervous system infections in São Paulo State, Brazil. J. Med. Virol. 2020;92:3849–3856. doi: 10.1002/jmv.26131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26131</ArticleId><ArticleId IdType="pubmed">32492248</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong V., Mey C., Eloit M., Zhu H., Danet L., Huang Z., Zou G., Tarantola A., Cheval J., Perot P., et al. Molecular epidemiology of human enterovirus 71 at the origin of an epidemic of fatal hand, foot and mouth disease cases in Cambodia. Emerg. Microbes. Infect. 2016;5:e104. doi: 10.1038/emi.2016.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.101</ArticleId><ArticleId IdType="pmc">PMC5113052</ArticleId><ArticleId IdType="pubmed">27651091</ArticleId></ArticleIdList></Reference><Reference><Citation>Upala P., Apidechkul T., Suttana W., Kullawong N., Tamornpark R., Inta C. Molecular epidemiology and clinical features of hand, foot and mouth disease in northern Thailand in 2016: A prospective cohort study. BMC Infect. Dis. 2018;18:630. doi: 10.1186/s12879-018-3560-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3560-4</ArticleId><ArticleId IdType="pmc">PMC6282397</ArticleId><ArticleId IdType="pubmed">30522440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu P.-Y., Lu P.-L., Tsai Y.-L., Hsi E., Yao C.-Y., Chen Y.-H., Hsu L.-C., Wang S.-Y., Wu H.-S., Lin Y.-Y., et al. Spatiotemporal phylogenetic analysis and molecular characterization of coxsackievirus A4. Infect. Genet. Evol. 2011;11:1426–1435. doi: 10.1016/j.meegid.2011.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2011.05.010</ArticleId><ArticleId IdType="pubmed">21635970</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-S., Dong X.-G., Qin M., Xie Z.-P., Gao H.-C., Yang J.-Y., Yang X.-X., Li D.-D., Li J., Duan Z.-J. Outbreak of febrile illness caused by coxsackievirus A4 in a nursery school in Beijing, China. Virol. J. 2015;12:92. doi: 10.1186/s12985-015-0325-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-015-0325-1</ArticleId><ArticleId IdType="pmc">PMC4495935</ArticleId><ArticleId IdType="pubmed">26084565</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Li C., Liu L., Liu X., Shang S., Mao H., Zhang Y. Molecular epidemiology of enterovirus from children with herpangina or hand, foot, and mouth disease in Hangzhou, 2016. Arch. Virol. 2019;164:2565–2571. doi: 10.1007/s00705-019-04356-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-019-04356-0</ArticleId><ArticleId IdType="pubmed">31321585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-Y., Li Y., Xu A.-Q., Zhang Y., Tao Z.-X., Liu G.-F., Liu Y., Song L.-Z., Zhang L., Yan B.-Y., et al. Identification and phylogenic analysis of Coxsackie-virus B5 during an outbreak of aseptic meningitis in Shandong. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31:64–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">20302702</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz A., Egerer R., Braun H., Schmidtke M., Rimek D., Kroh C., Hennig B., Groth M., Sauerbrei A., Zell R. Analysis of an echovirus 18 outbreak in Thuringia, Germany: Insights into the molecular epidemiology and evolution of several enterovirus species B members. Med. Microbiol. Immunol. 2016;205:471–483. doi: 10.1007/s00430-016-0464-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0464-z</ArticleId><ArticleId IdType="pubmed">27369854</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J., Miao Z., Lyu H., Zhou J., Gong L., Mao H., Sun Y., Zhang Y. Etiology and molecular-epidemiological characteristics of viral meningoencephalitis of Zhejiang province in 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36:280–284.</Citation><ArticleIdList><ArticleId IdType="pubmed">25975409</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuno K., Miyatake C., Nishijima H., Hotta C., Ogawa T., Asano T. Coxsackievirus B5 Aseptic Meningitis in Infants in Chiba Prefecture, Japan, in 2016. J. Nippon Med. Sch. 2018;85:187–190. doi: 10.1272/jnms.JNMS.2018_85-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1272/jnms.JNMS.2018_85-28</ArticleId><ArticleId IdType="pubmed">30135347</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui A., Yu D., Zhu Z., Meng L., Li H., Liu J., Liu G., Mao N., Xu W. An outbreak of aseptic meningitis caused by coxsackievirus A9 in Gansu, the People’s Republic of China. Virol. J. 2010;7:72. doi: 10.1186/1743-422X-7-72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-72</ArticleId><ArticleId IdType="pmc">PMC2907575</ArticleId><ArticleId IdType="pubmed">20367886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabbaraju K., Wong S., Chan E.N.Y., Tellier R. Genetic characterization of a Coxsackie A9 virus associated with aseptic meningitis in Alberta, Canada in 2010. Virol. J. 2013;10:93. doi: 10.1186/1743-422X-10-93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-93</ArticleId><ArticleId IdType="pmc">PMC3620579</ArticleId><ArticleId IdType="pubmed">23521862</ArticleId></ArticleIdList></Reference><Reference><Citation>Smuts H., Cronje S., Thomas J., Brink D., Korsman S., Hardie D. Molecular characterization of an outbreak of enterovirus-associated meningitis in Mossel Bay, South Africa, December 2015–January 2016. BMC Infect. Dis. 2018;18:709. doi: 10.1186/s12879-018-3641-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3641-4</ArticleId><ArticleId IdType="pmc">PMC6311073</ArticleId><ArticleId IdType="pubmed">30594238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Yuan S., Zhang C., Wang Y., Wang Y., He G., Zhang S., Altmeyer R., Zou G. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother. 2015;59:2654–2665. doi: 10.1128/AAC.05108-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C., Kang H., Kim D.-E., Song J.-H., Choi M., Kang M., Lee K., Kim H.S., Shin J.S., Jeong H., et al. Antiviral activity of micafungin against enterovirus 71. Virol. J. 2016;13:99. doi: 10.1186/s12985-016-0557-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0557-8</ArticleId><ArticleId IdType="pmc">PMC4907259</ArticleId><ArticleId IdType="pubmed">27296985</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F., Zhao X., Hu S., Li J., Yin L., Mei S., Liu T., Wang Y., Ren L., Cen S., et al. Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry. Sci. Rep. 2016;6:33150. doi: 10.1038/srep33150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33150</ArticleId><ArticleId IdType="pmc">PMC5016833</ArticleId><ArticleId IdType="pubmed">27608771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng S., Meng X., Huang Q., Lei N., Zeng L., Jiang X., Guo X. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int. J. Antimicrob. Agents. 2019;53:362–369. doi: 10.1016/j.ijantimicag.2018.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2018.12.009</ArticleId><ArticleId IdType="pubmed">30599241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-M. Milrinone in Enterovirus 71 Brain Stem Encephalitis. Front. Pharmacol. 2016;7:82. doi: 10.3389/fphar.2016.00082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00082</ArticleId><ArticleId IdType="pmc">PMC4809901</ArticleId><ArticleId IdType="pubmed">27065870</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y.-T., Wang S.-M., Chen S.-H. Anti-inflammatory and antiviral effects of minocycline in enterovirus 71 infections. Biomed. Pharmacother. 2019;118:109271. doi: 10.1016/j.biopha.2019.109271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109271</ArticleId><ArticleId IdType="pubmed">31377467</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner B., Dittmann S., Funke C., Überla K., Piper C., Niehaus K., Horstkotte D., Farr M. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflamm. Res. 2014;63:267–276. doi: 10.1007/s00011-013-0695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-013-0695-z</ArticleId><ArticleId IdType="pubmed">24316867</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke C., Farr M., Werner B., Dittmann S., Überla K., Piper C., Niehaus K., Horstkotte D. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Pt 8J. Gen. Virol. 2010;91:1959–1970. doi: 10.1099/vir.0.020065-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.020065-0</ArticleId><ArticleId IdType="pubmed">20392896</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazina E.V., Smidansky E.D., Holien J.K., Harrison D.N., Cromer B.A., Arnold J.J., Parker M.W., Cameron C.E., Petrou S. Amiloride is a competitive inhibitor of coxsackievirus B3 RNA polymerase. J. Virol. 2011;85:10364–10374. doi: 10.1128/JVI.05022-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05022-11</ArticleId><ArticleId IdType="pmc">PMC3196452</ArticleId><ArticleId IdType="pubmed">21795353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Chen Y., Jiang J., Zhou A., Pan L., Chen Q., Qian Y., Chu M., Chen C. Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene. 2014;547:195–201. doi: 10.1016/j.gene.2014.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2014.06.003</ArticleId><ArticleId IdType="pubmed">24905653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X.-Y., Li B.-F. Clinical effect of carvedilol in treatment of children with severe hand-foot-mouth disease caused by enterovirus 71 infection. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21:796–800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7389901</ArticleId><ArticleId IdType="pubmed">31416505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., de Boer S.M., van der Linden L., Bauer L., Lyoo H.R., Maté M.J., Lichière J., Canard B., Lelieveld D., Omta W., et al. Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob. Agents Chemother. 2016;60:2627–2638. doi: 10.1128/AAC.02182-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02182-15</ArticleId><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Li-Sha G., Jing-Lin Z., Li L., Guang-Yi C., Xiao-Wei L., Yue-Chun L. Nicotine inhibits the production of proinflammatory cytokines of mice infected with coxsackievirus B3. Life Sci. 2016;148:9–16. doi: 10.1016/j.lfs.2016.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2016.02.003</ArticleId><ArticleId IdType="pubmed">26851533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.-C., Luo Q., Ge L.-S., Chen Y.-H., Zhou N.-D., Zhang T., Guan X.-Q., Lin J.-F. Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis. Biochem. Biophys. Res. Commun. 2013;431:450–455. doi: 10.1016/j.bbrc.2012.12.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.12.147</ArticleId><ArticleId IdType="pubmed">23333383</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A., Zhang H., Wu S. Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm. Res. 2010;59:255–262. doi: 10.1007/s00011-009-0093-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-009-0093-8</ArticleId><ArticleId IdType="pubmed">19774449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.-Y., Li J.-N., Xia H.H.-X., Zhang S.-L., Zhong J., Wu Y.-Y., Miao S.-K., Zhou L.-M. Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3. Life Sci. 2013;92:1186–1194. doi: 10.1016/j.lfs.2013.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2013.05.010</ArticleId><ArticleId IdType="pubmed">23702425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.-B., Rao B.-F., Chang J., Liao X.-G., Cao Y.-D. Effects of captopril on myocardial energy metabolism in mice with viral myocarditis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003;15:485–488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12919652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Strating J.R.P.M., El Kazzi P., Lorenzo Lopez M., Ulferts R., van Hoey C., Maté M.J., Langer T., et al. Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner. ACS Infect. Dis. 2019;5:1609–1623. doi: 10.1021/acsinfecdis.9b00179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00179</ArticleId><ArticleId IdType="pmc">PMC6747591</ArticleId><ArticleId IdType="pubmed">31305993</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Guo X. Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance. Virol. J. 2016;13:168. doi: 10.1186/s12985-016-0626-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0626-z</ArticleId><ArticleId IdType="pmc">PMC5057454</ArticleId><ArticleId IdType="pubmed">27724948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Kim C., Kim D.-e., Song J.-H., Choi M., Choi K., Kang M., Lee K., Kim H.S., Shin J.S., et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral. Res. 2015;124:1–10. doi: 10.1016/j.antiviral.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.011</ArticleId><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H.-Y., Lu W.-W., Wu K.-Y., Lin C.-W., Kung S.-H. Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J. Gen. Virol. 2016;97:1122–1133. doi: 10.1099/jgv.0.000431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000431</ArticleId><ArticleId IdType="pubmed">26879094</ArticleId></ArticleIdList></Reference><Reference><Citation>Leipner C., Grün K., Müller A., Buchdunger E., Borsi L., Kosmehl H., Berndt A., Janik T., Uecker A., Kiehntopf M., et al. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovasc. Res. 2008;79:118–126. doi: 10.1093/cvr/cvn063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvn063</ArticleId><ArticleId IdType="pubmed">18326555</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Zhou H., Zhang X., Liu X., Wang J., Zhang C., Ma X., Quan C., Zheng Z. Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. Infect. Genet. Evol. 2020;81:104210. doi: 10.1016/j.meegid.2020.104210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104210</ArticleId><ArticleId IdType="pubmed">32004757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammer E., Nietzsche S., Rien C., Kühnl A., Mader T., Heller R., Sauerbrei A., Henke A. The anti-obesity drug orlistat reveals anti-viral activity. Med. Microbiol. Immunol. 2015;204:635–645. doi: 10.1007/s00430-015-0391-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-015-0391-4</ArticleId><ArticleId IdType="pubmed">25680890</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Xu M., Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral. Res. 2013;97:183–194. doi: 10.1016/j.antiviral.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.-R., Weng K.-F., Stollar V., Li M.-L. Viral protein synthesis is required for Enterovirus 71 to induce apoptosis in human glioblastoma cells. J. Neurovirol. 2008;14:53–61. doi: 10.1080/13550280701798980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280701798980</ArticleId><ArticleId IdType="pubmed">18300075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.-W., Huang H.-J., Wang Y.-F., Lee Y.-P., Huang C.-C., Yu C.-K. Methylene blue-mediated photodynamic inactivation as a novel disinfectant of enterovirus 71. J. Antimicrob. Chemother. 2010;65:2176–2182. doi: 10.1093/jac/dkq301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkq301</ArticleId><ArticleId IdType="pubmed">20719762</ArticleId></ArticleIdList></Reference><Reference><Citation>Molin Y., Frisk P., Hjelm E., Blomberg J., Friman G., Ilbäck N.-G. Arsenic trioxide influences viral replication in target organs of coxsackievirus B3-infected mice. Microbes. Infect. 2010;12:1027–1034. doi: 10.1016/j.micinf.2010.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.07.003</ArticleId><ArticleId IdType="pubmed">20638482</ArticleId></ArticleIdList></Reference><Reference><Citation>Marton J., Albert D., Wiltshire S.A., Park R., Bergen A., Qureshi S., Malo D., Burelle Y., Vidal S.M. Cyclosporine A Treatment Inhibits Abcc6-Dependent Cardiac Necrosis and Calcification following Coxsackievirus B3 Infection in Mice. PLoS ONE. 2015;10:e0138222. doi: 10.1371/journal.pone.0138222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138222</ArticleId><ArticleId IdType="pmc">PMC4574283</ArticleId><ArticleId IdType="pubmed">26375467</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.-Y., Jeong H.I., Park C.-W., Yoon J., Ko J., Nam S.-J., Lim B.-K. Cholic Acid Attenuates ER Stress-Induced Cell Death in Coxsackievirus-B3 Infection. J. Microbiol. Biotechnol. 2018;28:109–114. doi: 10.4014/jmb.1708.08009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1708.08009</ArticleId><ArticleId IdType="pubmed">29032641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zou G., Bailly B., Xu S., Zeng M., Chen X., Shen L., Zhang Y., Guillon P., Arenzana-Seisdedos F., et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg. Microbes. Infect. 2014;3:e62. doi: 10.1038/emi.2014.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Qing J., Sun Y., Rao Z. Suramin inhibits EV71 infection. Antiviral. Res. 2014;103:1–6. doi: 10.1016/j.antiviral.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Soumajit S., Tamil Selvan R.P., Bhanuprakash V. In vitro antiviral efficacy of pleconaril and ribavirin on foot-and-mouth disease virus replication. Virusdisease. 2019;30:562–570. doi: 10.1007/s13337-019-00559-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-019-00559-w</ArticleId><ArticleId IdType="pmc">PMC6917675</ArticleId><ArticleId IdType="pubmed">31890754</ArticleId></ArticleIdList></Reference><Reference><Citation>Niklasson B., Klitz W., Juntti-Berggren L., Berggren P.O., Lindquist L. Effectiveness of Antivirals in a Type 1 Diabetes Model and the Move Toward Human Trials. Viral. Immunol. 2020;33:594–599. doi: 10.1089/vim.2020.0039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2020.0039</ArticleId><ArticleId IdType="pubmed">32758075</ArticleId></ArticleIdList></Reference><Reference><Citation>Klitz W., Niklasson B. Extending the Enterovirus Lead: Could a Related Picornavirus be Responsible for Diabetes in Humans? Microorganisms. 2020;8:1382. doi: 10.3390/microorganisms8091382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8091382</ArticleId><ArticleId IdType="pmc">PMC7565261</ArticleId><ArticleId IdType="pubmed">32927606</ArticleId></ArticleIdList></Reference><Reference><Citation>Niklasson B., Lindquist L., Klitz W., Fredrikson S., Morgell R., Mohammadi R., Netherlands Brain B., Karapetyan Y., Englund E. Picornavirus May Be Linked to Parkinson’s Disease through Viral Antigen in Dopamine-Containing Neurons of Substantia Nigra. Microorganisms. 2022;10:599. doi: 10.3390/microorganisms10030599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10030599</ArticleId><ArticleId IdType="pmc">PMC8953350</ArticleId><ArticleId IdType="pubmed">35336174</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>